Effect of Vitamin E and DHA on Non-Alcoholic Fatty Liver Disease (NAFLD)
N
Naga Chalasani, MD
Primary Investigator
Not Recruiting
18 years - 100 years
All
Phase
N/A
30 participants needed
1 Location
Brief description of study
Researchers are looking for ways to help treat NAFLD. Previous studies have shown that Vitamin E and Docosahexaenoic Acid Ethyl Ester (DHA EE) may be useful for NAFLD.
Detailed description of study
Participants will begin with screening to include health history and report of medications, vitamins, and herbal supplements used.
Participants will be randomly assigned to take either vitamin E and placebo, Docosahexaeonic acid ethyl ester (DHA EE) and placebo, Vitamin E and DHA EE, or placebo. All are soft gel capsules and will be taken once daily with food.
Participants will complete 5 study visits (including the screening visit), which will include demographic questions; health and medication questions; vital signs; height, weight, and waist measurement; blood testing; questionnaires; urine pregnancy test (for women of childbearing potential).
Researchers will also contact each participant by phone one month after beginning the study.
Participants may also be asked to volunteer to test if the MRI scan has the capabilities to perform an advanced liver fat measurement technique called Proton Density Fat Fraction (PDFF). The scan takes less than 10 minutes and does not involve the use of MRI dye (gadolinium).
Participants will receive varying amounts after each completed study visit, for a total of up to $525 for full participation in this study. The breakdown of compensation per visit is included in the consent form provided prior to participation.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: NAFLD, non-alcoholic fatty liver disease, liver disease
-
Age: 18 years - 100 years
-
Gender: All
Individuals at least 18 years of age with a diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) within the past 4 years.
Individuals with other acute or chronic liver disease, or history of bariatric surgery, will not be eligible.
Individuals using anti-NASH drugs will not be eligible.
Individuals cannot consume fish oil for 2 months prior to entering the study.
Women who are pregnant or breastfeeding will not be eligible.
Updated on
01 Aug 2024.
Study ID: 1911964958
